Ziopharm Oncology traded at $1.75 this Friday September 30th, decreasing $0.23 or 11.62 percent since the previous trading session. Looking back, over the last four weeks, Ziopharm Oncology lost 28.87 percent. Over the last 12 months, its price fell by 4.90 percent. Looking ahead, we forecast Ziopharm Oncology to be priced at 1.68 by the end of this quarter and at 1.53 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
1.75
Daily Change
-11.62%
Yearly
-4.90%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Amgen 226.64 -1.77 -0.77% 5.95%
AstraZeneca 9,945.00 12.00 0.12% 13.36%
Baxter International 55.59 0.29 0.52% -30.88%
Biogen 260.80 -3.49 -1.32% -8.15%
Bioline Rx 0.92 0.02 2.68% -66.55%
Bristol-Myers Squibb 71.48 -0.23 -0.32% 20.80%
Corcept Therapeutics 25.54 -0.50 -1.92% 29.78%
Curis 0.74 -0.01 -1.71% -90.58%
Gilead Sciences 62.98 -0.09 -0.14% -8.14%
GlaxoSmithKline 1,306.20 -9.60 -0.73% -5.73%
Intercept Pharmaceuticals 13.44 -2.97 -18.10% -9.49%
Immunogen 4.80 0.10 2.13% -15.34%
Incyte Corp 67.57 0.96 1.44% -0.94%
Ionis Pharmaceuticals 44.91 0.63 1.42% 33.90%
J&J 164.66 0.13 0.08% 2.61%
Karyopharm Therapeutics 5.50 0.13 2.42% -5.50%
Merck & Co 86.81 0.17 0.20% 15.58%
Novartis 75.36 0.44 0.59% -0.92%
Pfizer 44.30 0.14 0.32% 3.00%
PTC Therapeutics 51.78 1.43 2.84% 37.24%
Regeneron Pharmaceuticals 698.50 6.68 0.97% 22.37%
Roche Holding 322.05 1.80 0.56% -6.72%
Sangamo BioSciences 5.04 0.17 3.39% -45.63%
TG Therapeutics 6.25 0.26 4.34% -81.46%
Verastem 0.86 -0.004 -0.50% -72.08%
Intrexon 2.11 0.06 2.93% -57.72%
Ziopharm Oncology 1.75 -0.23 -11.62% -4.90%

Indexes Price Day Year
USND 10747 9.70 0.09% -26.22%
US2000 1688 12.69 0.76% -24.71%

Ziopharm Oncology
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.